Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balicatib dose-finding study in painful knee osteoarthritis
2004-001754-92Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of balicatib in osteoarthritis (OA) and knee osteoarthritis (OA) (4 arms), sponsored by Novartis. Primary endpoint: Change in total cartilage volume of the target knee after 12 months. Started Jan 2005; status: completed.
02
Drugs
balicatib
03
Conditions
osteoarthritis (OA)knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2004-001754-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001754-92.